Such concerns are particularly pronounced for GLP-1R-targeted nanomedicines, as GLP-1R is endogenously expressed in multiple organs, including the pancreas, kidneys, lungs, heart, and brain [555]
doi: 10.1007/s40618-021-01533-4 96 FaienzaMFBrunettiGFintiniDGrugniGWasniewskaMGCrinAet al
One study suggested that GLP-1RAs exert direct endothelial protective effects by activating the GLP-1R-dependent AMPK/Akt/eNOS pathway
How to Apply the Findings as a Health and Exercise Professional As a health and exercise professional, these findings present you with both opportunities and challenges
SUSTAIN6 trial: Showed a 26% relative risk reduction in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke
Together, these factors may increase the risk of serious side effects related to GLP-1 use